

****REPRESENTATIVE DATASHEET******Matched-Pair Antibody Set
for ELISA of human
Antithrombin antigen (ATIII)**Sufficient reagent for **5 x 96 well plates**

Product #: ATIII-EIA
Lot #: XXXX
Expiry Date: XXXX

1348 Sandhill Drive, Ancaster, Ontario, Canada L9G 4V5
905-304-9896 • 800-903-6020 • fax 905-304-9897

Store at 2 -8°C

For Research Use Only
Not for use in diagnostic procedures.

Description of Antithrombin (ATIII)

Antithrombin, also known as Antithrombin III (ATIII), is a member of the SERPIN family of proteinase inhibitors and the primary inhibitor of thrombin in plasma. It is produced in the liver and circulates in plasma at ~200 µg/ml (~3.5 µM). Antithrombin inhibits a broad spectrum of serine proteases including thrombin, activated forms of factor X, factor IX, factor XI, factor XII, as well as kallikrein, plasmin and urokinase. Enzyme inhibition by antithrombin occurs through proteolytic cleavage at Arg³⁸⁵-Ser³⁸⁶ and subsequent rapid formation of a stable, inactive 1:1 enzyme-antithrombin complex. Heparin has a profound accelerating effect on the inhibitory activity of antithrombin towards some enzymes. For example, the rate of inhibition of thrombin and activated factor X is increased 1000-fold in the presence of optimal concentrations of heparin, whereas heparin has relatively little effect on the inhibition rate of activated factor XI, activated factor XII and kallikrein. Antithrombin is a single chain molecule with a molecular weight of 59 kDa. Interaction with thrombin results in an SDS-stable thrombin-antithrombin complex of 96 kDa¹⁻³.

Principle of Sandwich-style ELISA

Affinity-purified antibody to ATIII is coated onto the wells of a microtitre plate. The plates are washed and plasma or other fluids containing ATIII are applied. The coated antibody will capture the ATIII in the sample. After washing the plate to remove unbound material, a peroxidase conjugated second antibody to ATIII is added to the plate to bind to the captured ATIII. After washing the plate to remove unbound conjugated antibody, the peroxidase activity is expressed by incubation with o-phenylenediamine (OPD). After a fixed development time the reaction is quenched with the addition of H₂SO₄ and the colour produced is quantified using a microplate reader. The colour generated is proportional to the concentration of ATIII present in the sample.

Document OPI0062, rev 4

Supplied Materials:

- 1. Capture Antibody (ATIII-EIA-C):** One yellow-capped vial containing 0.5 ml of polyclonal affinity purified anti-ATIII antibody for coating plates.
- 2. Detecting Antibody (ATIII-EIA-D):** Five neutral-capped tubes each containing 10 ml of pre-diluted peroxidase conjugated polyclonal anti-ATIII antibody for detection of captured ATIII.

Store antibodies at 2-8°C**Materials Required but not Provided:**

- 1. Coating Buffer:** 50 mM Carbonate
1.59g of Na₂CO₃ and 2.93g of NaHCO₃ up to 1 litre. Adjust pH to 9.6. Store at 2-8°C up to 1 month.
- 2. PBS:** (base for wash buffer)
8.0g NaCl, 1.15g Na₂HPO₄, 0.2g KH₂PO₄ and 0.2g KCl, up to 1 litre. Adjust pH to 7.4, if necessary. Store up to 1 month at 2-8°C, discard if there is evidence of microbial growth.
- 3. Wash Buffer and Sample Diluent:** PBS-Tween (0.1%,v/v)
To 1 litre of PBS add 1.0 ml of Tween-20.
Check that the pH is 7.4. Store at 2-8°C up to 1 week.
- 4. Substrate Buffer:** Citrate-Phosphate buffer pH 5.0
2.6g Citric acid and 6.9g Na₂HPO₄ up to a final volume of 500 ml with purified H₂O. Store at 2-8°C up to 1 month.
- 5. OPD Substrate:** (o-Phenylenediamine.2HCl) **TOXIC!**
(5mg tablets: Sigma # P-6912). Make up immediately before use. Dissolve 5mg OPD in 12 ml substrate buffer then add 12 µl 30% H₂O₂. Do not store.

- 6. Stopping Solution:** 2.5 M H₂SO₄

Caution: VERY CORROSIVE! GENERATES HEAT ON DILUTION! Where stock sulphuric acid is 18 Molar, add 13.9 ml to 86 ml H₂O. Store at room temperature.

7. Other:

Microplates, 96-well Immulon 4-HBX (<http://www.labsystems.fi>)
Microplate washer (optional)
Microplate reader.
Optional: VisuCal™ Antigen Calibrator Plasma

Assay Procedure:

1. Coating of plates:

Dilute the capture antibody 1/100 in coating buffer (preferably in a polypropylene tube) and immediately add 100 µl to every well in the plate. Incubate 2 hours at room temperature or overnight at 2-8°C.

2. Blocking:

Blocking is not required under the conditions described. Washing the plate with PBS-Tween is sufficient to block non-specific interactions. Wash plate X 3 with wash buffer.

3. Samples:

Reference plasma is diluted 1/2,000 (100%) then serial 1/2's down to 1/64,000 (3.13%). Sample plasmas are diluted 1/4,000, 1/8,000 & 1/16,000. All dilutions are made in PBS-Tween. Apply 100 µl/well and incubate plate @ 22°C for 90 minutes. Wash plate X 3 with wash buffer.

4. Detecting Antibody:

Apply the pre-diluted detecting antibody, 100 µl to each well. Incubate plate @ 22°C for 60 minutes. Wash plate X 3 with wash buffer.

5. OPD Substrate:

Apply 100 µl of freshly prepared OPD substrate to every well. Allow colour to develop for 10-15 minutes then stop colour reaction with the addition of 50 µl/well of 2.5 M H₂SO₄. The plate can be read at wavelength of 490 nm.

Calculation of Results:

The construction of a proper reference curve is of no less importance than any other aspect of the assay. A reference curve should be constructed by plotting the known concentration of standards versus absorbance. This can be done manually using graph paper, or by using curve-fitting computer software. In our experience, the dose response curves of most immunoassays tend to be sigmoid in shape. Although linear regions can be identified within the curve, the best overall fit is often obtained using an algorithm that provides a weighted theoretical model of fit throughout the entire curve, such as a 4-parameter or 5-parameter logistic curve fit^{4,5}. In general, the simplest model that defines the concentration-response relationship should be used⁶.

The "back-fit" test is a simple and reliable method to determine if a curve-fitting method is appropriate. In this test, the apparent concentrations for the absorbance values of each standard point are read from the reference curve. The derived values are compared to the assigned values. An appropriate curve fitting method will produce derived values that closely match assigned values throughout the range of the curve, within user-defined limits⁶. The coefficient of determination (R^2) is a valuable indicator of the overall fit, but should not be used by itself in the selection of a curve fitting method, as a poor fit in a particular region of the curve may not be evident from this value alone^{5,6}.

In the quality control of this product we have determined that under the conditions described above, a reference curve that is constructed using serial dilutions of normal pooled plasma, will produce a correlation coefficient (R^2) of at least 0.980 using a semi-log fit, and an R^2 of at least 0.990 using a 4-parameter logistic curve fit algorithm. However, the performance characteristics of in-house assays developed using this product in other laboratories may vary slightly from ours. Different curve fitting methods may be employed but we recommend that the back-fit test be applied as evidence that the fitting method is appropriate.

Technical Notes:

- This paired antibody product is intended to facilitate the end user in establishing an in-house immunoassay for research purposes only. It must not be used for diagnostic applications. Assay validation is the responsibility of the end user and should be done according to user-defined protocols⁶.
- Reference calibrators should be of the same matrix and anticoagulant as the samples to be tested (example serum or plasma, citrate or EDTA)
- Do not use samples diluted less than 1/100, as falsely high readings may result.
- The optimal colour development time should be determined empirically as the time required to obtain an absorbance of at least 1.000 at 490 nm for the 100% reference point, not to exceed 20 minutes.
- Rheumatoid factor in samples may interfere in ELISA by binding to the capture and/or detecting antibodies.
- The wells should not be allowed to become dry. Keep plate covered or in a humid chamber during incubations.
- Capture antibody is supplied in a 50% glycerol solution and can be centrifuged briefly in a micro-centrifuge to gather residual reagent from the cap and walls of the tube.

References:

1. Damus PS, Rosenberg RD; Antithrombin - Heparin Cofactor; Methods in Enzymology 45, pp 653-669, 1976.
2. Harpel PC; Blood Proteolytic Enzyme Inhibitors: Their Role in Modulating Blood Coagulation and Fibrinolytic Enzyme Pathways; in Hemostasis and Thrombosis, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 738-747, J.B. Lippincott Co., Philadelphia PA, USA, 1982.
3. Griffith MJ, Noyes CM, Church FC; Reactive Site Peptide Structural Similarity between Heparin Cofactor II and Antithrombin III; JBC:260, pp 2218-2225, 1985.
4. Nix,B, Wild D, in Immunoassays, A Practical Approach, editor J.P. Gosling, pp. 239-261, Oxford University Press, 2000.
5. NCCLS. Evaluation of the Linearity of Quantitative Analytical Methods; Proposed Guideline - Second Edition. NCCLS Document EP6-P2 (ISBN 1-56238-446-5, NCCLS, Wayne, Pennsylvania USA, 2001.
6. FDA Guidance for Industry. Bioanalytical Method Validation; May 2001, available on the internet: www.fda.gov/cder/guidance/index.htm

Related Products:

Cat #: EIA-CSA-1	VisuCal™ Antigen Calibrator, 1 x 1ml
Cat #: EIA-CSA-5	VisuCal™ Antigen Calibrator, 5 x 1ml
Cat #: GAAT-IG	Goat anti-human ATIII, whole IgG from antiserum
Cat #: GAAT-AP	Goat anti-human ATIII, affinity-purified IgG (APIgG)
Cat #: SAAT-IG	Sheep anti-human ATIII, whole IgG from antiserum
Cat #: SAAT-AP	Sheep anti-human ATIII, affinity-purified IgG (APIgG)
Cat #: SAAT-APHRP	Sheep anti-human ATIII, APIgG-peroxidase
Cat #: SAAT-APFTC	Sheep anti-human ATIII, FITC Conjugated APIgG
Cat #: SAAT-APBIO	Sheep anti-human ATIII, biotinylated APIgG
Cat #: MATIII-EIA	Paired antibody set for ELISA of murine ATIII
Cat #: TAT-EIA	Paired antibody ELISA of Thrombin-ATIII complexes
Cat #: AT-NU10	Paired antibody set for ATIII neutralization in plasma
Cat #: ATIII-DP	Human plasma deficient in ATIII, immune depleted
Cat #: ATIII-LDP	Human plasma deficient in ATIII, lyophilized
Cat #: ATHC-DP	Human ATIII & HCII def plasma, immune depleted
Cat #: ATHC-LDP	Human ATIII & HCII def plasma, lyophilized

Visit our site (www.affinitybiologicals.com) for details.

Limited Warranty: This product is warranted to perform in accordance with its labelling and literature. Affinity Biologicals Inc. disclaims any implied warranty of merchantability or fitness for any other purposes, and in no event will Affinity Biologicals Inc. be liable for any consequential damages arising out of aforesaid express warranty.

Manufactured in Canada by:
AFFINITY BIOLOGICALS INC.
1348 Sandhill Drive
Ancaster, ON CANADA L9G 4V5
Tel: (905) 304-9896
(800) 903-6020
Fax: (905) 304-9897
info@affinitybiologicals.com